Literature DB >> 22389301

Adjuvant chemoradiation for gastric cancer: multicentric study of the Anatolian Society of Medical Oncology.

Mehmet Kucukoner1, Abdurrahman Isikdogan, Erkan Arpaci, Mehmet Bilici, Dogan Uncu, Bulent Cetin, Faysal Dane, Mevlude Inane, Mehmet Ali Kaplan, Kerim Cayir, Tarkan Yetisyigit, Nuriye Ozdemir, Ali Inal, Sercan Aksoy, Necati Alkis, Salim Basol Tekin, Celalettin Eroglu, Serdar Turhal, Mustafa Benekli, Suleyman Buyukberber.   

Abstract

BACKGROUND/AIMS: The aims of this study were to report the clinical outcomes of adjuvant chemo-radiotherapy after curative resection in 637 patients with gastric cancer.
METHODOLOGY: The retrospective analysis included 637 patients with resectable gastric cancer and stage IB-IV (M0) from 8 medical centers between 2003 and 2010. The patients were treated with 5FU-leucovorin and radiotherapy according to Schema for INT-0116.
RESULTS: Of the 637 patients, the median of overall survival (OS) was 43.7 months and relapse free survival (RFS) was 36.6 months. OS rates were 84%, 45%, 40% while RFS rates were 81%, 45% and 35% at 1, 3 and 5-years, respectively. Hematological and gastrointestinal toxicities (grade 1-4) were observed in 35% and 36.5% of patients, respectively. In univariate analysis, according to the Lauren classification, tumor grade, T stage, N stage, type of operation (total gastrectomy or subtotal) and surgery resection margin (R0 or R1) were found as prognostic factors on RFS and OS (p<0.05). In multivariate analysis, T stage, N stage and surgical margins were found as effective factors on OS. T stage, N stage and Lauren classification were factors affecting RFS.
CONCLUSIONS: Adjuvant chemo-radiotherapy after curative resection of gastric cancer was feasible, with acceptable toxicities in the Turkish population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22389301     DOI: 10.5754/hge11709

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  2 in total

1.  Adjuvant radiochemotherapy in locally advanced gastric cancer : Treatment results and analysis of possible prognostic factors.

Authors:  Mercedes Martín Sánchez; Maria Ángeles Pérez Escutia; David Lora Pablos; Sandra Guardado Gonzales; Ana María Cabezas Mendoza; Arantxa Campos Bonel; Héctor Pérez Montero; Rafael D'Ambrosi; José Fermín Pérez-Regadera Gómez
Journal:  Strahlenther Onkol       Date:  2017-07-03       Impact factor: 3.621

2.  A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer.

Authors:  Kunning Wang; Enxiao Li; Rita A Busuttil; Joseph C Kong; Sharon Pattison; Joseph J Y Sung; Jun Yu; Emad M El-Omar; Julie A Simpson; Alex Boussioutas
Journal:  Ther Adv Med Oncol       Date:  2020-07-23       Impact factor: 8.168

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.